EMEA-001715-PIP01-14-M04

Table of contents

Key facts

Invented name
Fluad Tetra
Active substance
  • Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2)
  • Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage)
  • Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage)
  • Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1)
Therapeutic area
Vaccines
Decision number
P/0355/2020
PIP number
EMEA-001715-PIP01-14-M04
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of influenza infection
Route(s) of administration
Intramuscular use
Contact for public enquiries
Seqirus Netherlands B.V.

Tel. +31 646951054
E-mail: pip.seq@seqirus.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating
Average
View 1 rating
1 rating